Karyopharm Therapeutics Inc.
KPTI | NASDAQ
$1.88
+$0.02 (+1.08%)
Sep 22, 2026, 2:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 146.07M | 145.24M | 146.03M | 157.07M | 209.82M | 108.09M |
Cost of Revenue | 5.95M | 6.01M | 4.94M | 5.21M | 3.4M | 2.71M |
Gross Profit | 140.12M | 139.23M | 141.09M | 151.86M | 206.42M | 105.38M |
Operating Income | -90.71M | -119.44M | -129.54M | -142.2M | -98.27M | -171.85M |
Interest Income | 2.77M | 7.4M | 10.94M | 2.36M | 582K | 2.82M |
Pretax Income | -196M | -76.37M | -142.78M | -164.92M | -123.82M | -195.96M |
Net Income | -196.04M | -76.42M | -143.1M | -165.29M | -124.09M | -196.27M |
Selling & General & Admin | 105.21M | 115.44M | 131.88M | 145.4M | 143.85M | 126.42M |
Research & Development | 125.62M | 143.23M | 138.75M | 148.66M | 160.84M | 150.81M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 230.83M | 258.67M | 270.63M | 294.06M | 304.69M | 277.23M |
Interest Expense | 45.85M | 37.42M | 23.82M | 25M | 26.05M | 27.14M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 236.77M | 264.68M | 275.57M | 299.28M | 308.09M | 279.94M |
Income Tax Expense | 43K | 57K | 323K | 369K | 268K | 309K |
Shares Outstanding (Basic) | 10.94M | 8.12M | 7.61M | 5.46M | 5.01M | 4.8M |
Shares Outstanding (Diluted) | 10.94M | 8.12M | 7.61M | 5.46M | 5.01M | 4.8M |
EPS (Basic) | -17.93 | -9.41 | -18.79 | -30.28 | -24.75 | -40.87 |
EPS (Diluted) | -17.93 | -9.41 | -18.79 | -30.28 | -24.75 | -40.87 |
EBITDA | -149.85M | -38.6M | -118.42M | -139.31M | -96.99M | -167.85M |
EBIT | -150.15M | -38.94M | -118.95M | -139.93M | -97.77M | -168.82M |
Depreciation & Amortization | 296K | 340K | 530K | 621K | 789K | 972K |
Add to Watchlist
Select watchlists to add or remove KPTI